Literature DB >> 7818312

Normothermia versus hypothermia during cardiopulmonary bypass: a randomized, controlled trial.

M Tönz1, T Mihaljevic, L K von Segesser, E R Schmid, H I Joller-Jemelka, P Pei, M I Turina.   

Abstract

To evaluate the influence of perfusion temperature on systemic effects of cardiopulmonary bypass (CPB), 30 patients undergoing elective coronary artery bypass grafting were randomly assigned to either normothermic (warm, n = 14, 36 degrees C) or hypothermic (cold, n = 16, 28 degrees C) CPB. Serial hemodynamic measurements and blood samples were obtained before, during and after the CPB procedure. During CPB, there were no differences between both groups in the need for vasopressors (norepinephrine, phenylephrine), urinary output, or fluid balance. In the early postoperative period, normothermic CPB patients had significantly lower systemic vascular resistance and higher cardiac index measurements (mean +/- standard error: systemic vascular resistance, 880 +/- 27 versus 1,060 +/- 57 dyne.s.cm-5, p = 0.025; cardiac index, 3.6 +/- 0.1 versus 2.9 +/- 0.1 L.min-1.m-2, p = 0.01) without differences in the administration of vasoactive drugs. Blood loss was significantly higher in patients after hypothermic CPB (median [range] body surface area: 370 [180-560] versus 490 [280-2,120] mL/m2, p = 0.0006), with a greater need for transfusion of erythrocytes and fresh frozen plasma. Plasma levels of tumor necrosis factor and soluble tumor necrosis factor receptors increased during and after CPB, independent of perfusion temperature. This study suggests a significant influence of CPB temperature and respective perfusion management on postoperative hemodynamics and blood loss. Normothermic CPB is not associated with additional systemic adverse effects.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7818312     DOI: 10.1016/0003-4975(94)00718-m

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  8 in total

1.  [Evaluation of cerebral circulation during cardiopulmonary bypass using near-infrared spectroscopy].

Authors:  T Ohata; Y Sawa; S Ohtake; M Nishimura; N Hirata; K Kagisaki; S Taketani; T Yamaguchi; H Matsuda
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-07

2.  [Early recovery after valvular heart surgery].

Authors:  M Nakayama; K Eishi; S Nakano; M Kuro; K Kumon
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-05

3.  Platelet Functions in Cardiopulmonary Bypass Surgery.

Authors:  S J Varghese; M K Unni; N Mukundan; Ramji Rai
Journal:  Med J Armed Forces India       Date:  2011-07-21

4.  Normothermic cardiopulmonary bypass and cardioplegia reduce inotropic requirements and creatine kinase-MB after coronary artery bypass graft surgery.

Authors:  Mitsuru Kunihiro; Tsutomu Shimabukuro; Toshiaki Horie; Koichiro Nandate; Kazuyoshi Ishida; Katsuhiro Seo; Hiroshi Takeshita
Journal:  J Anesth       Date:  1997-12       Impact factor: 2.078

5.  Warm blood cardioplegia.

Authors:  I Birdi; M B Izzat; A J Bryan; G D Angelini
Journal:  Br Heart J       Date:  1995-11

6.  Influence of hypothermia on right atrial cardiomyocyte apoptosis in patients undergoing aortic valve replacement.

Authors:  Evaristo Castedo; Raquel Castejón; Emilio Monguio; Sebastian Ramis; Carlos G Montero; Santiago Serrano-Fiz; Raul Burgos; Cristina Escudero; Juan Ugarte
Journal:  J Cardiothorac Surg       Date:  2007-01-23       Impact factor: 1.637

7.  Part II. Comparison of Neurodevelopmental Outcomes Between Normothermic and Hypothermic Pediatric Cardiopulmonary Bypass.

Authors:  Claire E Hannon; Zachary Osman; Cathy Grant; Emma M L Chung; Antonio F Corno
Journal:  Front Pediatr       Date:  2019-11-05       Impact factor: 3.418

Review 8.  Therapeutic Hypothermia and the Risk of Hemorrhage: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Chih-Hung Wang; Nai-Chuan Chen; Min-Shan Tsai; Ping-Hsun Yu; An-Yi Wang; Wei-Tien Chang; Chien-Hua Huang; Wen-Jone Chen
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.